- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Similarity.
Displaying page 1 of 2.
EudraCT Number: 2011-003106-24 | Sponsor Protocol Number: 721103 | Start Date*: 2011-10-06 |
Sponsor Name:Baxter Innovations GmbH | ||
Full Title: Effectiveness of PREFLUCEL vaccination against infection with seasonal influenza virus in an adult and elderly population aged 50 years and older | ||
Medical condition: To verify the effectiveness of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2011/2012 and 2012/2013 season respectively, manufactured us... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001505-90 | Sponsor Protocol Number: 18CH049 | Start Date*: 2018-10-01 | ||||||||||||||||
Sponsor Name:CHU de Saint Etienne | ||||||||||||||||||
Full Title: Decolonization of patients carrying S. aureus before cardiac surgery: study of the risk factors associated with failure | ||||||||||||||||||
Medical condition: Decolonization of S. aureus nasal carriers before cardiac surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005071-40 | Sponsor Protocol Number: AVT03-GL-C01 | Start Date*: 2022-10-31 | |||||||||||
Sponsor Name:Alvotech Swiss AG | |||||||||||||
Full Title: A Randomized, Double-Blind, Parallel Design, Repeat Dose, 2-arm, Multicenter Study Comparing the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profiles of AVT03 and US-Prolia® in Postmenopa... | |||||||||||||
Medical condition: Osteoporosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-002894-48 | Sponsor Protocol Number: 1301.1 | Start Date*: 2012-09-14 | ||||||||||||||||
Sponsor Name:Boehringer Ingelheim International GmbH | ||||||||||||||||||
Full Title: Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, ac... | ||||||||||||||||||
Medical condition: Moderately to severely active Rheumatoid Arthritis that has had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) EE (Completed) PT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) NO (Prematurely Ended) GR (Completed) ES (Prematurely Ended) BG (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003420-46 | Sponsor Protocol Number: MYL-1410A-3001 | Start Date*: 2015-07-22 | |||||||||||
Sponsor Name:Mylan GmbH (Mylan) | |||||||||||||
Full Title: Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Mode... | |||||||||||||
Medical condition: Chronic Plaque-Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003287-37 | Sponsor Protocol Number: EMR200588-002 | Start Date*: 2016-03-15 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A randomized, double-blind, confirmatory trial to evaluate the efficacy, safety and immunogenicity of MSB11022 compared with European Union-Approved Humira® in subjects with moderate to severe chro... | |||||||||||||
Medical condition: moderate to severe plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) DE (Completed) GB (Completed) CZ (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005543-90 | Sponsor Protocol Number: 20130108 | Start Date*: 2014-08-26 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-Blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) PL (Completed) BG (Completed) EE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022529-14 | Sponsor Protocol Number: WC25501 | Start Date*: 2011-02-04 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche | |||||||||||||
Full Title: A phase III, double-blind, randomized, placebo-controlled, multi-center study evaluating the efficacy and safety of dalcetrapib on lipids, lipoproteins, apolipoproteins and markers of CV risk in pa... | |||||||||||||
Medical condition: Coronary Heart Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: Removed from public view |
EudraCT Number: 2006-002055-32 | Sponsor Protocol Number: PSD506-OAB-004 | Start Date*: 2006-10-09 | |||||||||||
Sponsor Name:Plethora Solutions Limited | |||||||||||||
Full Title: A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naïve or previously treated (washed out) patients with benign prostatic obstruct... | |||||||||||||
Medical condition: This study aims to assess the safety of PSD506 in men with benign prostatic enlargement (BPE) / benign prostatic obstruction (BPO) and lower urinary tract symptoms (LUTS) and an IPSS of 8-19, in li... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Prematurely Ended) IE (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001638-12 | Sponsor Protocol Number: mRNA-1010-P302 | Start Date*: 2022-09-29 | |||||||||||
Sponsor Name:ModernaTX, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older. | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) EE (Completed) BG (Completed) DK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002254-20 | Sponsor Protocol Number: 1297.9 | Start Date*: 2017-08-04 | |||||||||||
Sponsor Name:Boehringer Ingelheim International GmbH | |||||||||||||
Full Title: VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm,... | |||||||||||||
Medical condition: moderate to severe chronic plaque psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002283-41 | Sponsor Protocol Number: 151032-002 | Start Date*: 2017-09-11 |
Sponsor Name:HRA Pharma | ||
Full Title: A prospective, randomized, parallel-group study to assess the effects on ovarian activity of ellaOne (ulipristal acetate 30 mg single dose) taken after three consecutive days of missed combined ora... | ||
Medical condition: Emergency contraception | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-002765-34 | Sponsor Protocol Number: MabionCD20-003RA | Start Date*: 2021-10-21 | |||||||||||
Sponsor Name:Mabion S.A. | |||||||||||||
Full Title: A Double-Blind, Randomized, Parallel-Group Study to Investigate the Pharmacokinetic and Clinical Similarity Between MabionCD20 (manufactured in commercial scale), EU-approved MabThera® and US-licen... | |||||||||||||
Medical condition: Moderate-to-severe rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000695-19 | Sponsor Protocol Number: SB5-4001 | Start Date*: 2022-07-22 | |||||||||||
Sponsor Name:Samsung Bioepis Co., Ltd | |||||||||||||
Full Title: A Phase IV, Randomised, Double-blind, Parallel-group, Multiple-dose, Active Comparator, Multicentre Clinical Study to Evaluate the Pharmacokonetics, Efficacy, Safety, and Immunogenicity of SB5 Vers... | |||||||||||||
Medical condition: Moderate to severe plaque psioriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000542-18 | Sponsor Protocol Number: 20200497 | Start Date*: 2021-12-21 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared With ... | |||||||||||||
Medical condition: Moderate to Severe Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004532-18 | Sponsor Protocol Number: M10-239 | Start Date*: 2014-11-12 | |||||||||||
Sponsor Name:Abbott | |||||||||||||
Full Title: A Multi-Center, Open-Label Efficacy, Safety, and Pharmacokinetic Study of Adalimumab in Japanese Subjects With Active Ankylosing Spondylitis | |||||||||||||
Medical condition: Ankylosing Spondylitis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004558-33 | Sponsor Protocol Number: M10-240 | Start Date*: 2014-12-09 | |||||||||||
Sponsor Name:Abbott Japan Co., Ltd. | |||||||||||||
Full Title: A Multicenter, Open-label Study of the Safety, Efficacy, and Pharmacokinetics of the Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Rheumatoid Arthritis | |||||||||||||
Medical condition: Juvenile Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002336-31 | Sponsor Protocol Number: CT-P17-3.3 | Start Date*: 2022-10-20 | |||||||||||
Sponsor Name:CELLTRION, Inc | |||||||||||||
Full Title: A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
Medical condition: Moderate to Severe Chronic Plaque Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005588-28 | Sponsor Protocol Number: 000080 | Start Date*: 2013-06-04 | |||||||||||
Sponsor Name:Ferring International Pharmascience Center US, Inc. | |||||||||||||
Full Title: A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Follo... | |||||||||||||
Medical condition: Chronic idiopathic constipation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Completed) SK (Completed) HU (Prematurely Ended) CZ (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002930-19 | Sponsor Protocol Number: XBR1001 | Start Date*: 2019-02-25 | |||||||||||
Sponsor Name:Xbrane Biopharma | |||||||||||||
Full Title: A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration | |||||||||||||
Medical condition: Wet Age-related macular degeneration (AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) LT (Completed) HU (Completed) SK (Completed) LV (Completed) CZ (Completed) BG (Completed) PL (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
